Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study

PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies. PATIENTS AND METHODS: Lapatinib was admin...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Fouladi, Maryam, Stewart, Clinton. F., Blaney, Susan M., Onar-Thomas, Arzu, Schaiquevich, Paula, Packer, Roger J., Gajjar, Amar, Kun, Larry E., Boyett, James M., Gilbertson, Richard J.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2953974/
https://ncbi.nlm.nih.gov/pubmed/20713864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.4687
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires